The short version of pentadecapeptide fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-31. Anything still debated is marked as such rather than presented as settled.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength that captures the peptide backbone. The main peak area is reported as a percentage of total peak area, which serves as a conventional purity figure. Mass spectrometry provides an independent check on molecular mass and helps confirm the expected sequence. Additional tests may include amino acid analysis and water content determination. Results are only comparable when the same column, gradient, and detection settings are used.
Peptides are susceptible to hydrolysis, oxidation, and aggregation, and BPC-157 is no exception. The lyophilized powder form is generally more stable than a solution because residual moisture is low and molecular mobility is reduced. Once dissolved, the peptide is exposed to water, oxygen, and trace metal ions that accelerate degradation. Light exposure and repeated freeze-thaw cycles are also commonly cited as sources of loss. These general principles guide most handling recommendations found in supplier documentation.
Standard practice for the solid form is storage at minus twenty degrees Celsius or colder, kept dry and away from light. Containers are usually sealed with a desiccant to limit moisture uptake. Reconstituted solutions are typically held at two to eight degrees Celsius and used within a short window, because potency can decline over days to weeks depending on the buffer and concentration. Freezing an already dissolved sample may help, though repeated thawing is discouraged. Specific shelf-life claims vary between suppliers and are rarely supported by published stability studies.
| Property | Value | Notes |
|---|---|---|
| Typical subjects | Rats and mice | Animal models |
| Common routes | Injection and oral | Route varies by study |
| Reported dose range | Microgram to milligram per kg | Not standardized across work |
| Frequent endpoints | Tissue repair, angiogenesis | Marker-dependent |
| Human evidence | Limited | Mostly small or preliminary studies |
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
On May 5, 1961, Alan Shepard became the first American in space, launching in a ballistic trajectory on Mercury-Redstone 3, in a spacecraft he named Freedom 7. Though he did not achieve orbit like Gagarin, he was the first person to exercise manual control over his spacecraft's attitude and retro-rocket firing. After his successful return, Shepard was celebrated as a national hero, honored with parades in Washington, New York and Los Angeles, and received the NASA Distinguished Service Medal from President John F. Kennedy. American Virgil "Gus" Grissom repeated Shepard's suborbital flight in Liberty Bell 7 on July 21, 1961. Almost a year after the Soviet Union put a human into orbit, astronaut John Glenn became the first American to orbit the Earth, on February 20, 1962. His Mercury-Atlas 6 mission completed three orbits in the Friendship 7 spacecraft, and splashed down safely in the Atlantic Ocean, after a tense reentry, due to what falsely appeared from the telemetry data to be a loose heat-shield. On February 23, 1962, President Kennedy awarded Glenn with the NASA Distinguished Service Medal in a ceremony at Cape Canaveral Air Force Station. As the first American in orbit, Glenn became a national hero, and received a ticker-tape parade in New York City, reminiscent of that given for Charles Lindbergh. The United States launched three more Mercury flights after Glenn's: Aurora 7 on May 24, 1962, duplicated Glenn's three orbits, Sigma 7 on October 3, 1962, six orbits, and Faith 7 on May 15, 1963, 22 orbits (32.4 hours), the maximum capability of the spacecraft.
The 1946 elections saw the Muslim League secure 90 percent of the Muslim seats, supported by the landowners of Sindh and Punjab. This forced the Indian National Congress, initially skeptical of the League's representation of Indian Muslims, to acknowledge its significance. Jinnah's emergence as the voice of the Indian Muslims, compelled the British to consider their stance, despite their reluctance to partition India. In a final attempt to prevent partition, they proposed the Cabinet Mission Plan. As the Cabinet Mission failed, the British announced their intention to end rule by June 1948. Following rigorous discussions involving Viceroy of India, Lord Mountbatten of Burma, Muhammad Ali Jinnah of the All-India Muslim League, and Jawaharlal Nehru of Congress, the formal declaration to partition British India into two independent dominions—namely Pakistan and India—was issued by Mountbatten on the evening of 3 June 1947. In Mountbatten's oval office, the prime ministers of around a dozen major princely states gathered to receive their copies of the plan before its worldwide broadcast. At 7:00 P.M., All India Radio transmitted the public announcement, starting with the viceroy's address, followed by individual speeches from Nehru, and Jinnah. The founder of Pakistan Muhammad Ali Jinnah concluded his address with the slogan Pakistan Zindabad (Long Live Pakistan).
== Mechanism of action == In-vitro binding inhibition data showed that Epelsiban is a highly potent and selective non-peptide oxytocin antagonist with sub-namomolar potency at the human oxytocin receptor (hOTR) Ki = 0.13 nM and with>50000-fold, >63000-fold, and >31000-fold selectivity over the human V1a, V1b and V2 vasopressin receptors. It is also 100-fold more potent at the hOTR than atosiban (a marketed intravenous peptide oxytocin antagonist) and is 5-fold more potent against the hOTR, and more selective against the human vasopressin receptors, especially V2, than retosiban. High in vivo oxytocin antagonist potency was demonstrated in the anesthetized rat model, where uterine contractions were elicited by intravenous administration of oxytocin and reduction in uterine contractility was measured after subsequent intravenous administrations of increasing doses of Epelsiban, which gave an IC50 of 192nM.
Georg, German-trained medicinal chemist, professor of medicinal chemistry in the US Ellen Gleditsch (1879–1968), Norwegian radiochemist Paula T. Hammond (1963-), American chemical engineer, MIT professor Anna J. Harrison (1912–1998), American organic chemist Remziye Hisar (1902–1992), Turkish chemist, first woman chemist of Turkey Darleane C. Hoffman (1926–2025), American Nuclear chemist Icie Hoobler (1892–1984), American biochemist Dorothy Crowfoot Hodgkin (1910–1994), British crystallographer, Nobel prize in chemistry 1964 Donna M. Huryn, American organic chemist Clara Immerwahr (1870–1915), German chemist Allene Rosalind Jeanes (1906–1995), American organic chemist Malika Jeffries-EL, American organic chemist Irène Joliot-Curie (1897–1956), French chemist and nuclear physicist, Nobel Prize in Chemistry 1935 Madeleine M.
Minoxidil — first-line, low dose topical drug for hair loss, can also be used orally at a high dose for hypertension; oral minoxidil has been implicated in heart problems including pericardial effusion. Monoamine oxidase inhibitors — used for treatment-resistant depression; may have potentially lethal dietary and drug interactions which may trigger hypertensive crisis and/or serotonin syndrome. Thalidomide — originally prescribed for morning sickness, withdrawn in 1961 owing to widespread incidence of severe birth defects (phocomelia or tetraamelia) after prenatal use by pregnant women; approved by the US Food and Drug Administration for erythema nodosum leprosum (ENL) in 1998, and new cases of multiple myeloma (administered with dexamethasone) in 2008; also used "off-label" for rare cancers; can cause multiple severe side effects and cannot be prescribed to pregnant women. Tolcapone — used in patients with Parkinson's disease who are not appropriate candidates for other adjunctive therapies; use is restricted due to hepatotoxicity. Vigabatrin — used for extreme treatment-resistant epilepsy; carries risk of permanent vision loss.
Sources: en.wikipedia.org
== Treatment == Treatment is predominantly preventive. Avoidance of topical phenols and diets low in tyrosine may help. Replacement and repair of damaged tissue is also possible. Hydroquinone-induced exogenous ochronosis is an avoidable dermatosis that is exceedingly difficult to treat. However, some studies show that treatment may be possible with a Q-switched alexandrite (755 nm) laser. Individuals with this disorder are recommended to stop using hydroquinone-containing compounds. Awareness of this is important, as dermatologists may think the symptoms a patient is exhibiting are a melasma, and prescribe a hydroquinone-containing cream.
=== ENSO Costero === Coined by the Peruvian Comité Multisectorial Encargado del Estudio Nacional del Fenómeno El Niño (ENFEN), ENSO Costero, or ENSO Oriental, is the name given to the phenomenon where the sea-surface temperature anomalies are mostly focused on the South American coastline, especially from Peru and Ecuador. Studies point many factors that can lead to its occurrence, sometimes accompanying, or being accompanied, by a larger EP ENSO occurrence, or even displaying opposite conditions from the observed ones in the other Niño regions when accompanied by Modoki variations. ENSO Costero events usually present more localized effects, with warm phases leading to increased rainfall over the coast of Ecuador, northern Peru and the Amazon rainforest, and increased temperatures over the northern Chilean coast, and cold phases leading to droughts on the Peruvian coast, and increased rainfall and decreased temperatures on its mountainous and jungle regions. Because they don't influence the global climate as much as the other types, these events present lesser and weaker correlations to other significant ENSO features, neither always being triggered by Kelvin waves, nor always being accompanied by proportional Southern Oscillation responses. According to the Coastal Niño Index (ICEN), strong El Niño Costero events include 1957, 1982–83, 1997–98 and 2015–16, and La Niña Costera ones include 1950, 1954–56, 1962, 1964, 1966, 1967–68, 1970–71, 1975–76 and 2013.
== Artificial de-excitation == 180mTa can be forced to release its energy by X-rays. This was predicted theoretically in 1988 by C. B. Collins, although at that time this de-excitation mechanism had never been observed. This was observed in 180mTa by resonant photo-excitation of intermediate high levels of this nucleus (E ≈ 1 MeV), in 1999 by Belic and co-workers in the Stuttgart nuclear physics group. 178m272Hf is another reasonably stable nuclear isomer, with a half-life of 31 years and a remarkably high excitation energy for that life. In its natural decay, 2.45 MeV is released as gamma rays. As with 180mTa, it is thought that 178m2Hf can be stimulated into releasing its energy. Due to this, the substance has been studied as a possible source for gamma-ray lasers, and reports have indicated that the energy could be released very quickly, so that 178m2Hf can produce extremely high powers (on the order of exawatts). It was supposedly detected experimentally in the 2000s, but it was controversial and not independently confirmed. Other isomers have also been investigated as possible media for gamma-ray stimulated emission.
UK and international clinical practice guidelines do not recommend metformin as a first-line treatment or do not recommend it at all, except for people with glucose intolerance. The guidelines suggest clomiphene as the first medication option and emphasize lifestyle modification independently from medical treatment. Metformin treatment decreases the risk of developing type 2 diabetes in people with PMOS who exhibited impaired glucose tolerance at baseline. In Poland, metformin is listed as an approved and reimbursed treatment for PMOS.
Sources: en.wikipedia.org
A proteome is the entire set of proteins that is, or can be, expressed by a genome, cell, tissue, or organism at a certain time. It is the set of expressed proteins in a given type of cell or organism, at a given time, under defined conditions. Proteomics is the study of the proteome.
RAC/The Sunday Times Taste of Britain Best Restaurant Award 1984 Decanter Magazine Restaurant of the Year 1989 The Good Hotel Guide Cesar Award 1995 Egon Ronay's Guide Restaurant of the Year 1996 Hotel & Restaurant Magazine Seafood Restaurant of the Year 1998, 1999, 2000, 2001 and 2003 The AA Award – English Seafood Restaurant of the Year Award 2002 For the man:
=== Parkinson's disease === Apomorphine is used for the management of motor fluctuations in Parkinson's disease, particularly for the treatment of "off" episodes. "Off" episodes are periods during which motor symptoms such as rigidity, bradykinesia, or reduced mobility reemerge as the effects of dopaminergic medications wear off. Apomorphine can provide rapid improvement in motor symptoms. Apomorphine is administered in multiple pharmaceutical formulations. Intermittent subcutaneous injection is used as an acute treatment and has been shown to terminate "off" episodes in individuals with motor fluctuations not adequately controlled with oral therapy. Sublingual apomorphine film has been reported in a recent narrative review to produce rapid off‑to‑on conversion and clinically meaningful short‑term improvements in motor scores when used as an on‑demand treatment for off episodes in Parkinson's disease, but an MDS evidence‑based review judged the randomized‑trial data insufficient to conclude that intermittent apomorphine formulations (including sublingual film) provide sustained benefits in disability or quality of life over 12‑week treatment periods. Continuous subcutaneous infusion of apomorphine using a wearable infusion device is also prescribed for individuals with motor fluctuations. Continuous infusion treatment is used in patients whose symptoms are not adequately controlled with oral or transdermal therapies and has been shown to reduce daily "off" time.
Sources: en.wikipedia.org
Human data are limited. Most evidence comes from animal experiments and from small or uncontrolled reports. The absence of large trials means clinical effects and safety are not firmly established.
Frequently measured outcomes include wound healing, blood vessel growth, and tissue repair markers. Some work examines gastrointestinal protection. The choice of endpoint depends on the model used.
Different routes of administration and different animal models require different amounts. Studies also use varied timelines and measurement methods. This variation makes it difficult to combine results into a single standardized figure.
Reversed-phase HPLC separates the sample into peaks, and the main peak is expressed as a percentage of total peak area. Mass spectrometry is then used to confirm that the molecular mass matches the expected value.